user

Safety and effectiveness of eculizumab in Japanese patients with generalized myasthenia gravis: interim analysis of post-marketing surveillance (vol 14, pg 1, 2021)

被引：0
|
作者：
Murai, H.
Suzuki, S.
Hasebe, M.
机构：
来源：
THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS | 2021年 / 14卷
关键词：
D O I：
10.1177/17562864211049696
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Safety and effectiveness of eculizumab in Japanese patients with generalized myasthenia gravis: interim analysis of post-marketing surveillance
    Murai, Hiroyuki
    Suzuki, Shigeaki
    Hasebe, Miki
    Fukamizu, Yuji
    Rodrigues, Ema
    Utsugisawa, Kimiaki
    [J]. THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS, 2021, 14
  • [2] Safety and Effectiveness of Eculizumab for Patients with Generalized Myasthenia Gravis in Japan: Interim Analysis of Post-Marketing Surveillance
    Murai, H.
    Suzuki, S.
    Hasebe, M.
    Fukamizu, Y.
    Rodrigues, E.
    Utsugisawa, K.
    [J]. EUROPEAN JOURNAL OF NEUROLOGY, 2020, 27 : 485 - 486
  • [3] Real-world experience with eculizumab in Japanese patients with myasthenia gravis: Post-marketing surveillance data
    Takahashi, M.
    Masuda, M.
    Watanabe, M.
    Fukamizu, Y.
    Osawa, T.
    Kikui, H.
    Murai, H.
    [J]. EUROPEAN JOURNAL OF NEUROLOGY, 2023, 30 : 574 - 574
  • [4] Real-world effectiveness of eculizumab in generalized myasthenia gravis in Japan: 1-year post-marketing surveillance data
    Murai, Hiroyuki
    Suzuki, Shigeaki
    Fukamizu, Yuji
    Osawa, Takehiko
    Kikui, Hidekazu
    Utsugisawa, Kimiaki
    [J]. NEUROLOGY, 2022, 98 (18)
  • [5] TWO-YEAR POST-MARKETING SAFETY EXPERIENCE OF ECULIZUMAB IN PATIENTS WITH GENERALIZED MYASTHENIA GRAVIS IN THE UNITED STATES
    Muley, S.
    Muppidi, S.
    Levine, T.
    Rodrigues, E.
    Carrillo-Infante, C.
    Howard, J.
    [J]. MUSCLE & NERVE, 2020, 62 : S113 - S114
  • [6] Safety and effectiveness of eculizumab for adult patients with atypical hemolytic–uremic syndrome in Japan: interim analysis of post-marketing surveillance
    Hideki Kato
    Yoshitaka Miyakawa
    Yoshihiko Hidaka
    Norimitsu Inoue
    Shuichi Ito
    Shoji Kagami
    Shinya Kaname
    Masanori Matsumoto
    Masashi Mizuno
    Takahisa Matsuda
    Akihiko Shimono
    Shoichi Maruyama
    Yoshihiro Fujimura
    Masaomi Nangaku
    Hirokazu Okada
    [J]. Clinical and Experimental Nephrology, 2019, 23 : 65 - 75
  • [7] Safety and effectiveness of eculizumab for pediatric patients with atypical hemolytic–uremic syndrome in Japan: interim analysis of post-marketing surveillance
    Shuichi Ito
    Yoshihiko Hidaka
    Norimitsu Inoue
    Shinya Kaname
    Hideki Kato
    Masanori Matsumoto
    Yoshitaka Miyakawa
    Masashi Mizuno
    Hirokazu Okada
    Akihiko Shimono
    Takahisa Matsuda
    Shoichi Maruyama
    Yoshihiro Fujimura
    Masaomi Nangaku
    Shoji Kagami
    [J]. Clinical and Experimental Nephrology, 2019, 23 : 112 - 121
  • [8] Safety and effectiveness of eculizumab for pediatric patients with atypical hemolytic-uremic syndrome in Japan: interim analysis of post-marketing surveillance
    Ito, Shuichi
    Hidaka, Yoshihiko
    Inoue, Norimitsu
    Kaname, Shinya
    Kato, Hideki
    Matsumoto, Masanori
    Miyakawa, Yoshitaka
    Mizuno, Masashi
    Okada, Hirokazu
    Shimono, Akihiko
    Matsuda, Takahisa
    Maruyama, Shoichi
    Fujimura, Yoshihiro
    Nangaku, Masaomi
    Kagami, Shoji
    [J]. CLINICAL AND EXPERIMENTAL NEPHROLOGY, 2019, 23 (01) : 112 - 121
  • [9] Safety and effectiveness of eculizumab for adult patients with atypical hemolytic-uremic syndrome in Japan: interim analysis of post-marketing surveillance
    Kato, Hideki
    Miyakawa, Yoshitaka
    Hidaka, Yoshihiko
    Inoue, Norimitsu
    Ito, Shuichi
    Kagami, Shoji
    Kaname, Shinya
    Matsumoto, Masanori
    Mizuno, Masashi
    Matsuda, Takahisa
    Shimono, Akihiko
    Maruyama, Shoichi
    Fujimura, Yoshihiro
    Nangaku, Masaomi
    Okada, Hirokazu
    [J]. CLINICAL AND EXPERIMENTAL NEPHROLOGY, 2019, 23 (01) : 65 - 75
  • [10] Safety and effectiveness of empagliflozin in Japanese patients with type 2 diabetes: interim analysis from a post-marketing surveillance study
    Kaku, Kohei
    Chin, Rina
    Naito, Yusuke
    Iliev, Hristo
    Ikeda, Rie
    Ochiai, Kaori
    Yasui, Atsutaka
    [J]. EXPERT OPINION ON DRUG SAFETY, 2020, 19 (02) : 211 - 221
12345